Differential Effects of Aerobic, Resistance, and Combined Trainings on First- and Second-Phase Insulin Secretion and Glucose Effectiveness in Type 2 Diabetes: A Randomized Controlled Trial

有氧训练、阻力训练和联合训练对2型糖尿病患者第一时相和第二时相胰岛素分泌及葡萄糖利用效率的不同影响:一项随机对照试验

阅读:3

Abstract

OBJECTIVE: This randomized controlled trial evaluated the differential effects of aerobic training (AT), resistance training (RT), and combined training (CT) on biphasic insulin secretion and glucose effectiveness (GE) in patients with Type 2 diabetes mellitus (T2DM). METHODS: Forty-five male T2DM patients (mean age: 55.24 ± 8.17 years; disease duration: 12.51 ± 6.46 years; baseline HbA1c: 7.1% ± 1.0%) were randomized to 12-week AT (n = 11), RT (n = 11), CT (n = 11), or control (n = 12) groups. AT involved progressive aerobic exercise (25-45 min at 70%-75% maximum heart rate, thrice weekly). RT comprised nine multijoint exercises (2-3 sets, 8-12 repetitions, thrice weekly). CT combined the full AT protocol with a modified RT regimen (one set, twice weekly). First-phase insulin secretion (FPIS), second-phase insulin secretion (SPIS), and GE were quantified using validated models pre- and postintervention. RESULTS: Adjusting for baseline values, age, and diabetes duration, ANCOVA revealed significant between-group differences in FPIS (F[3, 38] = 8.64, p < 0.001, η (2) = 0.406), SPIS (F[3, 38] = 6.93, p < 0.001, η (2) = 0.354), and GE (F[3, 38] = 5.57, p = 0.003, η (2) = 0.305). CT elicited the greatest improvements: FPIS (53.4% ± 12.7%, p < 0.001), SPIS (38.9% ± 11.2%, p < 0.001), and GE (12.8% ± 4.6%, p = 0.001) versus control. AT enhanced FPIS (32.6% ± 10.3%, p = 0.001) and SPIS (21.7% ± 8.9%, p = 0.042), while RT improved FPIS (28.5% ± 9.8%, p = 0.006), SPIS (27.5% ± 9.4%, p = 0.012), and GE (10.7% ± 4.3%, p = 0.004). Regression analysis identified baseline β-cell function (β = -0.31, p = 0.020), adiposity reduction (β = -0.36, p = 0.008), and glycemic improvement (β = -0.42, p = 0.003) as predictors of FPIS gains (R (2) = 0.537). CONCLUSIONS: CT outperforms single-modality training in enhancing biphasic insulin secretion and GE in T2DM, supporting multimodal exercise as a cornerstone of diabetes management to improve β-cell function and glycemic control. TRIAL REGISTRATION: ClinicalTrials.gov identifier: IRCT2016042227529N1.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。